- ISIN
- US0887861088
- CUSIP
- 088786108
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 23, 2019
Highlights
- Market Cap
- $267.86M
- Enterprise Value
- -$228.51M
- EPS (TTM)
- -$2.74
- Total Revenue (TTM)
- $61.21M
- Gross Profit (TTM)
- $61.21M
- EBITDA (TTM)
- -$183.20M
- Year Range
- $3.80 - $9.16
- Target Price
- $10.67
- ROA (TTM)
- -31.39%
- ROE (TTM)
- -37.32%
- Avg. Volume (1M)
- 347K
- Avg. Volume Value (1M)
- $1.44M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BCYC Performance Chart
Bicycle Therapeutics plc (BCYC) is down 45.5% since the beginning of the year. At $4 per share, BCYC is trading 57.9% below its 52-week high of $9. Investors who bought $1,000 worth of BCYC shares 5 years ago would now be looking at an investment worth $122.
Loading charts...
Compare this symbol against anything
Returns By Period
Bicycle Therapeutics plc (BCYC) has returned -45.48% so far this year and -51.69% over the past 12 months.
Bicycle Therapeutics plc
- 1D
- -3.74%
- 1M
- -11.26%
- 6M
- -39.88%
- YTD
- -45.48%
- 1Y
- -51.69%
- 3Y*
- -45.97%
- 5Y*
- -34.33%
- 10Y*
- —
- ALL TIME*
- -15.87%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
BCYC Monthly Returns History
Based on dividend-adjusted daily data since May 23, 2019, BCYC's average daily return is +0.03%, while the average monthly return is +0.04%. At this rate, an investment would double in approximately 144.4 years.
Historically, 44% of months were positive and 56% were negative. The best month was Sep 2019 with a return of +55.2%, while the worst month was Apr 2022 at -46.5%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 5 months.
On a daily basis, BCYC closed higher 47% of trading days. The best single day was Jan 14, 2021 with a return of +28.5%, while the worst single day was Apr 11, 2022 at -38.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.32% | -10.75% | -19.02% | 1.72% | -0.64% | -9.59% | -8.96% | -45.48% | |||||
| 2025 | -4.36% | -18.07% | -22.61% | 0.82% | -3.97% | -15.45% | 22.59% | -13.38% | 4.88% | 4.26% | -7.31% | -5.35% | -49.43% |
| 2024 | -3.48% | 43.78% | -0.76% | -5.82% | -5.37% | -8.79% | 20.11% | -11.56% | 5.26% | 3.60% | -12.99% | -31.37% | -22.57% |
| 2023 | -6.69% | -17.70% | -6.42% | -7.10% | 21.36% | 6.42% | -3.61% | -11.63% | -7.59% | -25.09% | -4.32% | 25.56% | -38.92% |
| 2022 | -19.78% | -2.72% | -7.62% | -46.49% | -31.90% | 4.94% | 40.41% | 12.27% | -12.06% | 6.41% | 17.01% | 2.21% | -51.37% |
| 2021 | 49.36% | -5.74% | 18.20% | 3.78% | -4.84% | 2.92% | 4.08% | 12.97% | 16.50% | 23.59% | 4.57% | 13.25% | 239.11% |
Benchmark Metrics
Bicycle Therapeutics plc has an annualized alpha of -6.24%, beta of 0.91, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since May 23, 2019.
- This stock participated in 150.95% of S&P 500 Index downside but only 36.92% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -6.24%
- Beta
- 0.91
- R²
- 0.07
- Upside Capture
- 36.92%
- Downside Capture
- 150.95%
Return for Risk
Risk / Return Rank
BCYC ranks 5 for risk / return — above 5% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Bicycle Therapeutics plc (BCYC) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BCYC | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.48 | ||
| Sortino ratioReturn per unit of downside risk | -3.67 | ||
| Omega ratioGain probability vs. loss probability | 0.81 | 1.25 | -0.44 |
| Calmar ratioReturn relative to maximum drawdown | -0.97 | 2.00 | -2.97 |
| Martin ratioReturn relative to average drawdown | -1.54 | 8.49 | -10.03 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Bicycle Therapeutics plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Bicycle Therapeutics plc was 93.69%, occurring on Jul 29, 2026. The portfolio has not yet recovered.
The current Bicycle Therapeutics plc drawdown is 93.69%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-93.69%Jul 2026 | 4y 8mo | — | 4y 8moNov 2021 - now | — |
-53.96%Aug 2019 | 2mo 9d | 5mo 20d | 7mo 29dJun 2019 - Feb 2020 | — |
-41.61%Mar 2020 | 12d | 2mo 6d | 2mo 18dMar 2020 - May 2020 | COVID crash2020 |
-25.95%Mar 2021 | 24d | 28d | 1mo 22dFeb 2021 - Apr 2021 | — |
-20.84%Aug 2021 | 24d | 11d | 1mo 5dJul 2021 - Aug 2021 | — |
Drawdown Indicators
| BCYC | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.69% | -56.78% | -36.91% |
Max Drawdown (1Y)Largest decline over 1 year | -56.48% | -9.10% | -47.38% |
Max Drawdown (3Y)Largest decline over 3 years | -85.97% | -18.90% | -67.07% |
Max Drawdown (5Y)Largest decline over 5 years | -93.69% | -25.43% | -68.26% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -93.69% | -1.58% | -92.11% |
Average DrawdownAverage peak-to-trough decline | -50.02% | -10.70% | -39.32% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 35.76% | 2.14% | +33.62% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Bicycle Therapeutics plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Bicycle Therapeutics plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BCYC relative to other companies in the Biotechnology industry. Currently, BCYC has a P/S ratio of 4.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BCYC in comparison with other companies in the Biotechnology industry. Currently, BCYC has a P/B value of 0.5. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BCYC
Add Bicycle Therapeutics plc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BCYC